Siu et al. c omprehensively assessed the rapidly changing regulation and reimbursement environment for biologicals and biosimilars in Canada and the resultant implications. The current situation in Canada is compared with similar initiatives across different countries to enhance savings from biosimilars to improve the affordability of biologicals.
|Number of pages||5|
|Publication status||Published - 2019|